Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

18.02 -0.11 (-0.58%)
Streaming Delayed Price Updated: 10:43 AM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
Roivant Sciences Earnings Preview
 
Via Benzinga
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy
The market's dour reaction to Roivant Sciences' latest deal doesn't add up. 
Via The Motley Fool
FSR Stock Alert: What to Know as Fisker Drops Prices
Fisker stock is on the move Monday as investors in FSR react to news of a price drop for one version of the company's Ocean EV. 
Via InvestorPlace
PINS Stock Pops as Stifel Upgrades Pinterest
Pinterest stock is getting a boost on Monday after a Stifel analyst upgraded PINS to a 'buy' rating and increasing its price target. 
Via InvestorPlace
Why Is Roivant Sciences (ROIV) Stock Up Today?
ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates. 
Via InvestorPlace
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases. 
Via Investor's Business Daily
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal
Roche Holding AG (OTC: RHHBY) inked a deal to acquire  
Via Benzinga
What 8 Analyst Ratings Have To Say About Roivant Sciences
 
Via Benzinga
Analyst Expectations for Roivant Sciences's Future
 
Via Benzinga
What 9 Analyst Ratings Have To Say About Roivant Sciences
 
Via Benzinga
Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set... 
Via Benzinga
Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble.
The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck. 
Via Investor's Business Daily
3 No-Brainer Growth Stocks to Buy in October
These three top mid-cap stocks could be poised for a long-tailed growth spurt. 
Via The Motley Fool
8 Analysts Have This to Say About Roivant Sciences
 
Via Benzinga
Why Immunovant Stock Is Bolting Higher Today
The company may have best-in-class autoimmune disease therapy under its roof. 
Via The Motley Fool
Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday
Keybanc cut the price target for Danaher Corporation (NYSE: DHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market... 
Via Benzinga
Roivant Stock Price Outlook: Strong Pipeline Is A Catalyst
Roivant Sciences has 12 drugs in its pipeline. The company’s Immunovant subsidiary reported strong results for its drug. Roivant is in talks with Roche to sell its Chron’s disease for $7 billion. 
Via Talk Markets
Why Shares of Immunovant Are Soaring on Tuesday
Immunovant sees strong potential for an autoimmune disorder therapy. 
Via The Motley Fool
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi... 
Via Benzinga
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Why Is Autoimmune Disease-Focused Immunovant Stock Trading Higher Today?
Immunovant Inc (NASDAQ: IMVT), a unit of Roivant Sciences Ltd (NASDAQ: ROIV), announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in Immunoglobulin G (IgG)... 
Via Benzinga
These 2 Biotech Stocks Are Bucking a Down Market Tuesday
Stock index futures pointed to a lower open on Wall Street Tuesday morning. 
Via The Motley Fool
Roivant Sciences: Is Vivek Ramaswamy’s Biotech Stock A Buy?
Roivant Sciences stock price has entered a major bull run as investors remain optimistic about the company’s future. The shares surged to a high of $12.67 on Friday, reaching its highest level since... 
Via Talk Markets
Vivek Ramaswamy's Parallels With Warren Buffett Run Deeper Than Wanting To Make Roivant The 'Berkshire Hathaway Of Drug Development'
Presidential hopeful Vivek Ramaswamy and Warren Buffett may share different political ideologies but they have at least a couple of things in common. 
Via Benzinga
2 Supercharged Growth Stocks Billionaires Can't Stop Buying
A top hedge fund has been steadily buying these two growth stocks in 2023. 
Via The Motley Fool
If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here's How Much You'd Have Now
Roivant stock has outperformed the broader market and the biotech sector this year, mirroring the rise in the fortunes of its founder Vivek Ramaswamy. 
Via Benzinga
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease. 
Via Investor's Business Daily
Earnings Scheduled For August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.